Allergy Therapeutics (LON:AGY) Shares Down 17.4% – Here’s What Happened

Allergy Therapeutics plc (LON:AGY)’s stock price was down 17.4% during trading on Tuesday . The company traded as low as GBX 9 and last traded at GBX 9. Approximately 165,235 shares traded hands during mid-day trading, a decline of 40% from the average daily volume of 277,293 shares. The stock had previously closed at GBX 10.90.

Allergy Therapeutics Stock Up 9.5%

The stock’s fifty day moving average price is GBX 10.78 and its 200 day moving average price is GBX 10.38. The stock has a market cap of £693.41 million, a P/E ratio of -11.29, a price-to-earnings-growth ratio of -30.70 and a beta of 0.91. The company has a current ratio of 1.13, a quick ratio of 1.48 and a debt-to-equity ratio of 629.58.

Allergy Therapeutics (LON:AGY) last issued its quarterly earnings results on Tuesday, March 31st. The company reported GBX (0.38) EPS for the quarter. The company had revenue of GBX 3,628 million during the quarter. Allergy Therapeutics had a positive return on equity of 409.00% and a negative net margin of 85.46%. As a group, research analysts forecast that Allergy Therapeutics plc will post -2.56 earnings per share for the current fiscal year.

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.